Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Largely Ignored At Appropriations Subcommittee Mark-Up

This article was originally published in The Pink Sheet Daily

Executive Summary

Rep. DeLauro proposes only amendment, which did not affect FDA and was defeated, but also warns FDA cuts could endanger Americans’ health.

You may also be interested in...



FDA Spending Bill Goes To House Panel At Lower Level Than Senate

A House appropriations subcommittee on June 6 will mark up a bill that would give FDA $44 million less to spend in Fiscal 2013 than a measure produced by the Senate Appropriations Committee, indicating a conference committee will be the final arbiter of agency funding.

DTC User Fees Rejected By House Approps Panel As FDA Safety Funds Get Boost

The House Appropriations Committee opted for using federal money, rather than fees from industry, to finance speedier FDA review of direct-to-consumer television ads when it approved a $1.7 billion fiscal year 2008 funding package for the agency July 19

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS074244

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel